Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection.

Joana VasconcelosJoão DomingosLia BastosTeresa BaptistaKamal Mansinho
Published in: Case reports in infectious diseases (2022)
Chronic hepatitis B (CHB) is a potentially life-threatening and prevalent disease worldwide. Far from attaining the ultimate treatment goal, hepatitis B virus (HBV) infection eradication, the two current therapeutic options aim to prevent progression to end-stage liver disease, maintaining long-term suppression of HBV replication. Pegylated interferon- α (PEG-INF α ) is often poorly tolerated and disregarded considering the orally administered nucleos(t)ide analogues. However, PEG-INF α may achieve similar treatment endpoints with a finite course of treatment. We report a case of PEG-INF α -treated CHB that attained sustained off-treatment virological response with only 16 weeks of treatment, with loss of both HBeAg and HBsAg (this latter the optimal treatment endpoint).